Maryland Shields Vets From Penalties Over Pet Cannabis Recommendations

Maryland Governor Wes Moore signed legislation Tuesday creating legal protections for veterinarians who recommend medical cannabis treatments for animals. The new law prevents the State Board of Veterinary Medical Examiners from suspending licenses, issuing reprimands, or taking disciplinary action against veterinarians solely for cannabis recommendations to pet owners.

The veterinary cannabis market represents an emerging revenue opportunity within the broader medical marijuana sector. Pet owners increasingly seek alternative treatments for conditions like seizures, chronic pain, and anxiety in animals, creating demand that veterinarians previously couldn't address without professional risk. Maryland's approach removes regulatory barriers that have limited veterinary participation in cannabis therapeutics.

This regulatory shift follows similar moves in states like California and Nevada, where veterinary cannabis protections have generated new patient categories and expanded market addressable size. Cannabis companies focused on pet products, including publicly traded operators with veterinary partnerships, benefit from increased professional endorsement and legitimized distribution channels through veterinary clinics.

Maryland's medical cannabis program generated $628 million in sales during 2023, with patient counts exceeding 140,000 registered users. Adding veterinary recommendations expands the potential customer base beyond human patients, though animal cannabis products typically carry lower price points than human therapeutics. The legislation creates regulatory clarity that encourages veterinary engagement without federal scheduling conflicts.

The veterinary protection trend signals broader acceptance of cannabis therapeutics across medical disciplines. As more states adopt similar frameworks, cannabis operators gain access to professional recommendation networks that drive patient acquisition and market expansion. Maryland's move reinforces the ongoing normalization of cannabis medicine beyond traditional human applications, supporting long-term industry growth across multiple therapeutic categories.